IBDEI02Y ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,924,1,3,0)
 ;;=3^Hepatitis B w/o Hepatic Coma
 ;;^UTILITY(U,$J,358.3,924,1,4,0)
 ;;=4^B19.10
 ;;^UTILITY(U,$J,358.3,924,2)
 ;;=^5000552
 ;;^UTILITY(U,$J,358.3,925,0)
 ;;=B17.10^^6^104^17
 ;;^UTILITY(U,$J,358.3,925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,925,1,3,0)
 ;;=3^Hepatitis C w/o Hepatic Coma,Acute
 ;;^UTILITY(U,$J,358.3,925,1,4,0)
 ;;=4^B17.10
 ;;^UTILITY(U,$J,358.3,925,2)
 ;;=^5000542
 ;;^UTILITY(U,$J,358.3,926,0)
 ;;=B18.2^^6^104^18
 ;;^UTILITY(U,$J,358.3,926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,926,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,926,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,926,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,927,0)
 ;;=E03.9^^6^104^31
 ;;^UTILITY(U,$J,358.3,927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,927,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,927,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,927,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,928,0)
 ;;=E16.2^^6^104^28
 ;;^UTILITY(U,$J,358.3,928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,928,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,928,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,928,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,929,0)
 ;;=E78.0^^6^104^21
 ;;^UTILITY(U,$J,358.3,929,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,929,1,3,0)
 ;;=3^Hypercholesterolemia,Pure
 ;;^UTILITY(U,$J,358.3,929,1,4,0)
 ;;=4^E78.0
 ;;^UTILITY(U,$J,358.3,929,2)
 ;;=^5002966
 ;;^UTILITY(U,$J,358.3,930,0)
 ;;=E78.1^^6^104^23
 ;;^UTILITY(U,$J,358.3,930,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,930,1,3,0)
 ;;=3^Hyperglyceridemia,Pure
 ;;^UTILITY(U,$J,358.3,930,1,4,0)
 ;;=4^E78.1
 ;;^UTILITY(U,$J,358.3,930,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,931,0)
 ;;=E78.5^^6^104^26
 ;;^UTILITY(U,$J,358.3,931,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,931,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,931,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,931,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,932,0)
 ;;=E78.4^^6^104^25
 ;;^UTILITY(U,$J,358.3,932,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,932,1,3,0)
 ;;=3^Hyperlipidemia,Other
 ;;^UTILITY(U,$J,358.3,932,1,4,0)
 ;;=4^E78.4
 ;;^UTILITY(U,$J,358.3,932,2)
 ;;=^5002968
 ;;^UTILITY(U,$J,358.3,933,0)
 ;;=E87.1^^6^104^27
 ;;^UTILITY(U,$J,358.3,933,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,933,1,3,0)
 ;;=3^Hypo-osmolatlity & Hyponatremia
 ;;^UTILITY(U,$J,358.3,933,1,4,0)
 ;;=4^E87.1
 ;;^UTILITY(U,$J,358.3,933,2)
 ;;=^5003019
 ;;^UTILITY(U,$J,358.3,934,0)
 ;;=E87.5^^6^104^24
 ;;^UTILITY(U,$J,358.3,934,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,934,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,934,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,934,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,935,0)
 ;;=E87.6^^6^104^29
 ;;^UTILITY(U,$J,358.3,935,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,935,1,3,0)
 ;;=3^Hypokalemia
 ;;^UTILITY(U,$J,358.3,935,1,4,0)
 ;;=4^E87.6
 ;;^UTILITY(U,$J,358.3,935,2)
 ;;=^60610
 ;;^UTILITY(U,$J,358.3,936,0)
 ;;=G81.90^^6^104^10
 ;;^UTILITY(U,$J,358.3,936,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,936,1,3,0)
 ;;=3^Hemiplegia,Unspec
 ;;^UTILITY(U,$J,358.3,936,1,4,0)
 ;;=4^G81.90
 ;;^UTILITY(U,$J,358.3,936,2)
 ;;=^5004120
 ;;^UTILITY(U,$J,358.3,937,0)
 ;;=G81.91^^6^104^9
 ;;^UTILITY(U,$J,358.3,937,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,937,1,3,0)
 ;;=3^Hemiplegia Affecting Right Dominant Side
 ;;^UTILITY(U,$J,358.3,937,1,4,0)
 ;;=4^G81.91
 ;;^UTILITY(U,$J,358.3,937,2)
 ;;=^5004121
 ;;^UTILITY(U,$J,358.3,938,0)
 ;;=G81.92^^6^104^8
 ;;^UTILITY(U,$J,358.3,938,1,0)
 ;;=^358.31IA^4^2
